Article

Stem cells as a treatment for chronic liver disease and diabetes.

Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Handbook of experimental pharmacology 02/2007; DOI: 10.1007/978-3-540-68976-8_11
Source: PubMed

ABSTRACT Advances in stem cell biology and the discovery of pluripotent stem cells have made the prospect of cell therapy and tissue regeneration a clinical reality. Cell therapies hold great promise to repair, restore, replace or regenerate affected organs and may perform better than any pharmacological or mechanical device. There is an accumulating body of evidence supporting the contribution of adult stem cells, in particular those of bone marrow origin, to liver and pancreatic islet cell regeneration. In this review, we will focus on the cell therapy for the diseased liver and pancreas by adult haematopoietic stem cells, as well as their possible contribution and application to tissue regeneration. Furthermore, recent progress in the generation, culture and targeted differentiation of human haematopoietic stem cells to hepatic and pancreatic lineages will be discussed. We will also explore the possibility that stem cell technology may lead to the development of clinical modalities for human liver disease and diabetes.

0 Bookmarks
 · 
96 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Hepatic stem cells are capable to self-renew and to differentiate into all types of cells in the liver, including hepatic progenitors, mature hepatocytes and cholangiocytes. Aims This review summarizes the recent advances in animal studies and the results of clinical trials over the last few decades. Results Studies in numerous animal models of liver diseases have demonstrated the efficacy of hepatic stem cells. Clinical studies of hepatic stem cells are also promising for a variety of hepatic diseases. Conclusions With the accumulation of innovative and creative works, hepatic stem cells therapy will be a new approach for liver diseases.
    Hepatology International 6(3). · 2.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The traditional view that adult human liver tumors, mainly hepatocellular carcinoma (HCC), arise from mature cell types has been challenged in recent decades. The results of several studies suggest that HCC can be derived from liver stem cells. There are four levels of cells in the liver stem cell lineage: hepatocytes, hepatic stem cells/oval cells, bone marrow stem cells and hepato-pancreas stem cells. However, whether HCC is resulted from the differentiation block of stem cells and, moreover, which liver stem cell lineage is the source cell of hepatocarcinogenesis remain controversial. In this review, we focus on the current status of liver stem cell research and their roles in carcinogenesis of HCC, in order to explore new approaches for stem cell therapy of HCC.
    Frontiers of Medicine in China 02/2008; 2(1):1-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was conducted to evaluate the effect of mesenchymal stem cells (MSCs) and a novel curcumin derivative (NCD) on HepG2 cells (hepatoma cell line) and to investigate their effect on Notch1 signaling pathway target genes. HepG2 cells were divided into HepG2 control group, HepG2 cells treated with MSC conditioned medium (MSCs CM), HepG2 cells treated with a NCD, HepG2 cells treated with MSCs CM and NCD, and HepG2 cells treated with MSCs CM (CM of MSCs pretreated with a NCD). Expression of Notch1, Hes1, VEGF, and cyclin D1 was assessed by real-time, reverse transcription-polymerase chain reaction (RT-PCR) in HepG2 cells. In addition, HepG2 proliferation assay was performed in all groups. Notch1 and its target genes (Hes1 and cyclin D1) were downregulated in all treated groups with more suppressive effect in the groups treated with both MSCs and NCD. Also, treated HepG2 cells showed significant decrease in cell proliferation rate. These data suggest that modulation of Notch1 signaling pathway by MSCs and/or NCD can be considered as a therapeutic target in HCC.
    BioMed research international. 01/2013; 2013:129629.

Full-text (3 Sources)

Download
20 Downloads
Available from
May 26, 2014